144 related articles for article (PubMed ID: 9411587)
1. [Cardio-protection and cardio-reparation in systemic arterial hypertension].
Vallés Belsué F; Anguita Sánchez M
Rev Esp Cardiol; 1997; 50 Suppl 4():49-52. PubMed ID: 9411587
[TBL] [Abstract][Full Text] [Related]
2. [Pathophysiology of left ventricular hypertrophy in arterial hypertension].
Vallotton MB; Braconi-Quintaje S; Lang U
Praxis (Bern 1994); 1997 Feb; 86(7):234-7. PubMed ID: 9139339
[TBL] [Abstract][Full Text] [Related]
3. The concept of cardioreparation: Part 1. Pathophysiology of remodelling.
Brilla CG; Murphy RL; Smits JF; Struijker Boudier HA; Tan LB
J Cardiovasc Risk; 1996 Jun; 3(3):281-5. PubMed ID: 8863100
[TBL] [Abstract][Full Text] [Related]
4. Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment.
Agabiti-Rosei E
Blood Press Suppl; 1997; 2():13-5. PubMed ID: 9495620
[TBL] [Abstract][Full Text] [Related]
5. [Relation between cardiac hypertrophy and changes in the large arterial trunks. Role of the renin-angiotensin system].
Benetos A
Arch Mal Coeur Vaiss; 1995 Feb; 88 Spec No 2():21-4. PubMed ID: 7646306
[TBL] [Abstract][Full Text] [Related]
6. [Arterial hypertension, correlated factors and cardiovascular risk].
Pessina AC; Casiglia E; Rossi GP; Semplicini A
Cardiologia; 1991 Dec; 36(12 Suppl 1):67-78. PubMed ID: 1841807
[TBL] [Abstract][Full Text] [Related]
7. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
Agabiti-Rosei E; Muiesan ML
J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
9. [Left ventricular hypertrophy: pathogenesis, diagnosis and therapy].
Nagy V
Orv Hetil; 2001 Jul; 142(26):1375-83. PubMed ID: 11478033
[TBL] [Abstract][Full Text] [Related]
10. [Cardioprotective and cardio-reparative drugs].
Bolaños F
Rev Esp Cardiol; 1997; 50 Suppl 4():53-6. PubMed ID: 9411588
[TBL] [Abstract][Full Text] [Related]
11. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
Gradman AH; Alfayoumi F
Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048
[TBL] [Abstract][Full Text] [Related]
12. Influence of dietary sodium on the renin-angiotensin-aldosterone system and prevalence of left ventricular hypertrophy by EKG criteria.
Williams JS; Williams GH; Jeunemaitre X; Hopkins PN; Conlin PR
J Hum Hypertens; 2005 Feb; 19(2):133-8. PubMed ID: 15361890
[TBL] [Abstract][Full Text] [Related]
13. Left ventricular and microvascular hypertrophy in essential hypertension: clinical relevance and prognostic implications.
Thürmann PA
Int J Clin Pharmacol Ther; 1997 May; 35(5):181-7. PubMed ID: 9174872
[TBL] [Abstract][Full Text] [Related]
14. Role of aldosterone in left ventricular hypertrophy in hypertension.
Matsumura K; Fujii K; Oniki H; Oka M; Iida M
Am J Hypertens; 2006 Jan; 19(1):13-8. PubMed ID: 16461184
[TBL] [Abstract][Full Text] [Related]
15. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
16. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
Schrier RW
J Am Soc Nephrol; 2009 Sep; 20(9):1888-93. PubMed ID: 19696226
[TBL] [Abstract][Full Text] [Related]
17. Hypertension to heart failure: a pathophysiological spectrum relating blood pressure, drug treatments and stroke.
Subramaniam V; Lip GY
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):703-13. PubMed ID: 19505285
[TBL] [Abstract][Full Text] [Related]
18. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
19. The what, why and how of hypertensive heart disease.
Weber KT
J Hum Hypertens; 1994 Sep; 8(9):665-75. PubMed ID: 7807496
[TBL] [Abstract][Full Text] [Related]
20. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
